Replies to post #206585 on Biotech Values

[iwfal]

PRTO:

Their clinical data to date sure looks like opportunistic highlighting of some endpoints sometimes, and not other times, as well as a dose of good, old-fashioned subgroup analyses.

Agree FWIW. (I am sorting through a long list of companies - and hadn't fully digested this one yet.)